Limits...
Pericyte protection by edaravone after tissue plasminogen activator treatment in rat cerebral ischemia.

Deguchi K, Liu N, Liu W, Omote Y, Kono S, Yunoki T, Deguchi S, Yamashita T, Ikeda Y, Abe K - J. Neurosci. Res. (2014)

Bottom Line: The number of pericytes and the overlap with NAGO decreased with tPA but recovered with edaravone 4 days after tMCAO with proliferation.Thus, tPA treatment damaged pericytes, resulting in the detachment from astrocytes and a decrease in glial cell line-derived neurotrophic factor secretion.However, treatment with edaravone greatly improved tPA-induced damage to pericytes.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.

Show MeSH

Related in: MedlinePlus

A: Double immunohistochemistry of PDGFRβ-positive pericytes (a–d, red), Ki67-positive cells (e–h, green), and merged images (i–l, arrowheads in double-positive cells) with a peak at 4 days (B). **P < 0.01 vs. SC. Scale bar = 100 μm.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4263311&req=5

fig02: A: Double immunohistochemistry of PDGFRβ-positive pericytes (a–d, red), Ki67-positive cells (e–h, green), and merged images (i–l, arrowheads in double-positive cells) with a peak at 4 days (B). **P < 0.01 vs. SC. Scale bar = 100 μm.

Mentions: The double-fluorescence study showed that PDGFRβ-positive cells (Fig. 2, red) were double positive with a small number of Ki67-positive cells (Fig. 2, green) in the SC group (7.5 ± 10.4/mm2) at 1 day (18.9 ± 13.4/mm2). The number of double-positive cells increased significantly, peaking at 4 days (Fig. 2, arrowheads; 132.3 ± 29.8/mm2, P < 0.01 vs. SC) and 14 days (Fig. 2, arrowheads; 71.8 ± 15.8/mm2, P < 0.01 vs. SC).


Pericyte protection by edaravone after tissue plasminogen activator treatment in rat cerebral ischemia.

Deguchi K, Liu N, Liu W, Omote Y, Kono S, Yunoki T, Deguchi S, Yamashita T, Ikeda Y, Abe K - J. Neurosci. Res. (2014)

A: Double immunohistochemistry of PDGFRβ-positive pericytes (a–d, red), Ki67-positive cells (e–h, green), and merged images (i–l, arrowheads in double-positive cells) with a peak at 4 days (B). **P < 0.01 vs. SC. Scale bar = 100 μm.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4263311&req=5

fig02: A: Double immunohistochemistry of PDGFRβ-positive pericytes (a–d, red), Ki67-positive cells (e–h, green), and merged images (i–l, arrowheads in double-positive cells) with a peak at 4 days (B). **P < 0.01 vs. SC. Scale bar = 100 μm.
Mentions: The double-fluorescence study showed that PDGFRβ-positive cells (Fig. 2, red) were double positive with a small number of Ki67-positive cells (Fig. 2, green) in the SC group (7.5 ± 10.4/mm2) at 1 day (18.9 ± 13.4/mm2). The number of double-positive cells increased significantly, peaking at 4 days (Fig. 2, arrowheads; 132.3 ± 29.8/mm2, P < 0.01 vs. SC) and 14 days (Fig. 2, arrowheads; 71.8 ± 15.8/mm2, P < 0.01 vs. SC).

Bottom Line: The number of pericytes and the overlap with NAGO decreased with tPA but recovered with edaravone 4 days after tMCAO with proliferation.Thus, tPA treatment damaged pericytes, resulting in the detachment from astrocytes and a decrease in glial cell line-derived neurotrophic factor secretion.However, treatment with edaravone greatly improved tPA-induced damage to pericytes.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.

Show MeSH
Related in: MedlinePlus